What premedication regimen should be given before infusing Ambisome (liposomal amphotericin B)?

Premedication for AmBisome (Liposomal Amphotericin B)

Routine premedication before AmBisome infusion is NOT recommended—premedicate only if infusion-related reactions occur during or after the first dose.

Key Recommendation

Liposomal amphotericin B (AmBisome/L-AmB) has a significantly improved tolerability profile compared to conventional amphotericin B deoxycholate, with infusion-related reactions occurring in only 5% of infusions 1. The evidence does not support empirical premedication for all patients.

Evidence-Based Approach

Initial Infusion Strategy

• Start without premedication for the first dose
• Infuse over 120 minutes initially 2
• Monitor for infusion-related reactions (fever, chills, rigors, nausea)
• If well-tolerated, infusion time may be reduced to 60 minutes for subsequent doses 2

When to Premedicate

Only premedicate patients who develop infusion-related reactions, then use prophylactically for subsequent infusions 3. The most common reactions are:

• Fever (occurs in ~51% with conventional AmB, but rare with liposomal formulation)
• Chills/rigors (~28% with conventional AmB)
• Nausea (~18%)

Premedication Regimen (When Indicated)

When premedication becomes necessary after documented reactions, consider:

• Acetaminophen 650-1000 mg PO 30-60 minutes before infusion
• Diphenhydramine 25-50 mg IV/PO 30 minutes before infusion
• Hydrocortisone 25-50 mg IV (reserve for severe reactions)

Administer 30-60 minutes prior to AmBisome infusion 3, 4.

Critical Clinical Context

The distinction between AmBisome and conventional amphotericin B deoxycholate is crucial here. A large prospective study of 397 patients receiving amphotericin B found that common pretreatment regimens (diphenhydramine, corticosteroids, acetaminophen, heparin) were similar in efficacy to no pretreatment in preventing infusion-related adverse events 3. However, this study primarily involved conventional amphotericin B.

AmBisome is far better tolerated: In neutropenic patients receiving AmBisome, infusion-related side effects occurred in only 15 of 331 infusions (5%), and only 2 patients (5%) required premedication 1. Another study confirmed that febrile reactions to AmBisome are rare 5.

Important Caveats

• Do not confuse formulations: AmBisome is NOT interchangeable with conventional amphotericin B deoxycholate or other lipid formulations on a mg-per-mg basis 2
• Infusion requirements: Must use 5% dextrose (never saline), and if using an in-line filter, pore diameter must be ≥1.0 micron 2
• If discomfort occurs during infusion: Increase infusion duration rather than automatically adding premedication 2

Practical Algorithm

1. First dose: No premedication, infuse over 120 minutes
2. Monitor: Watch for fever, chills, nausea during and after infusion
3. If reaction occurs: Treat symptomatically and slow infusion
4. Subsequent doses: Premedicate only those who had reactions
5. If well-tolerated: May reduce infusion time to 60 minutes

This approach avoids unnecessary medication exposure, reduces costs, and aligns with the evidence showing that empirical premedication cannot be routinely advocated 3.